

KELIE M'LISS REECE, Ph.D.

5801 Nicholson Lane, #516

North Bethesda, MD 20852

reecekmr@gmail.com; 301-300-1351

CAREER OBJECTIVE

To obtain a scientific editing position that will allow me to use my knowledge, research, and editing experience to review grants and manuscripts.

QUALIFICATIONS

- Extensive experience writing, editing, and reviewing scientific documents including grants and manuscripts
- Extensive experience working as a freelance editor and editing documents from non-native English speakers
- Very organized and detail-oriented
- Excellent written communication skills
- Expertise with Microsoft Office Suite
- Expertise in Molecular Pharmacology, Cancer Biology, Proteomics, Cell and Molecular Biology

EDUCATION

- Postdoctoral Fellow, Molecular Pharmacology Section, Medical Oncology Department, National Cancer Institute, Bethesda, MD 2010-2013
- Ph.D., Pharmacology, Vanderbilt University, Nashville, TN 2009
- B.A., Biology, Bryn Mawr College, Bryn Mawr, PA 1999

WORK EXPERIENCE

Regulatory Health Project Manager: US Food and Drug Administration, Silver Spring, MD 2017-present

Manages the drug review process from initial submission to the time of approval, termination, or withdrawal; implements regulations regarding new drugs and drug products and biologics approved by the organization in the application process; manages and coordinates the work of review team members (scientific, regulatory, and management) for specific drug application reviews; develops project plans including setting time frames, milestones, and endpoints.

Scientific Review Manager: SRA International, Inc., Frederick, MD 2013-2016

Managed all aspects of the scientific peer review of grant applications for the Product Development and Prevention Programs for the Cancer Prevention & Research Institute of Texas (CPRIT); developed an annual project plan for the scientific peer review of applications submitted for consideration; served as the primary client liaison for all technical aspects regarding the review process; configured peer review panels; managed the peer review meetings and oversaw the scientific integrity of the review process; ensured that program objectives were met on time.

RESEARCH EXPERIENCE

Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute Postdoctoral Fellow

Mentor: William D. Figg, Pharm.D., M.B.A. 2010-2013

- **Project 1:** Investigated the role of ERCC1 polymorphisms in sensitivity to treatment with platinum agents.
- **Project 2:** Investigated the effect of hypoxia-inducible factor 1 α (HIF-1 α)/p300 complex disruption in prostate cancer.
- **Project 3:** Investigated the cooperative regulation of HIF-1 α and androgen receptor-mediated signaling by dual treatment with MDV3100 and HIF-1 α inhibitors.
- **Project 4:** Investigated the effect of hypoxia on the expression of organic anion transporting polypeptide 1B3 in cancer.
- **Responsibilities:** Designed, implemented, managed, and executed multiple research projects; advised, supervised, and directed multiple undergraduate, graduate, and postbaccalaureate students on various projects; wrote, reviewed, and edited grant proposals and manuscript submissions.

- **Project:** "Regulation of the CaMKIV/PP2A Signaling Module." Investigated the molecular mechanisms governing the inactivation of CaMKIV by PP2A. This work laid the foundation for future studies directed towards understanding how the manipulation or intervention of this pathway could impact key biological processes regulated by this signaling complex, such as neuronal growth and function, and memory formation and maintenance. My research and expert writing skills led to the award of an NIH training grant.
- **Responsibilities:** Designed and executed experiments; organized graduate thesis research, including collaborations and mentoring committees; supervised undergraduate and high school students; contributed and assisted with the development and writing of grants and manuscripts.

TEACHING EXPERIENCE

Guest Lecturer, Molecular Targets and Cancer, Johns Hopkins University	2010-2011
Topic: Overview of Protein Kinases and Protein Phosphatases	
Topic: Angiogenesis Targets	
Teacher, AIDS Education Outreach Program	2002-2009
High school tutor, all subjects	2002-2008

EDITORIAL APPOINTMENTS

Scientific Editor:	2011-2017
Responsibilities include grant and manuscript copyediting, critiquing, polishing, and proofreading	
Enago English Proofreading	
Paper Talks	
Compuscript Ltd.	

Editorial Board:	2011-2013
Frontiers in Cancer Molecular Targets and Therapeutics	

Reviewer:	2010-2013
Cancer Biology and Therapy	Clinical Cancer Research
Oncogene	Journal of Molecular Medicine
Biochimie	American Journal of Pathology
Molecular Cancer Therapeutics	BMC Cancer
PNAS	Future Medicinal Chemistry

SELECTED PUBLICATIONS:

*Fernandez E.V., *Reece K.M., Ley A.M., Troutman S.M., Sissung T.M., Price D.K., Chau C.H., Figg W.D. (2015) Dual targeting of the androgen receptor and hypoxia-inducible factor 1a pathways synergistically inhibits castration-resistant prostate cancer cells. *Mol. Pharmacol.* 87(6):1006-12

*both authors contributed equally to this work

Reece, K.M., Richardson, E.D., Cook, K.M., Campbell, T.J., Pisle, S.T., Holly, A.J., Venzon, D.J., Liewehr, D.J., Chau, C.H., Price, D.K., Figg, W.D. (2014) Epidithiodiketopiperazines (ETPs) exhibit antiangiogenic and antitumor activity by disrupting the HIF-1a/p300 complex in a preclinical model of prostate cancer. *Mol. Cancer.* 13(91)

Reece, K.M., Figg, W.D. (2013) UGT1A1 polymorphisms and mutations in irinotecan-induced toxicity. In S. Yang & J. Dancey (Ed.) *Handbook of Therapeutic Biomarkers in Cancer* (pp 353-368). Chicago, IL: Pan Stanford Publishing

Gao, R., Reece, K.M., Sissung, T.M., Fu, S.H., Venzon, D., Price, D.K., Reed, E., Spencer, S.D., Price, D.K., Figg, W.D. (2012) Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N1118N? *BMJ Open.* 3(1)